Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- NBP1-86019 - Provider product page
- Provider
- Novus Biologicals
- Proper citation
- Novus Cat#NBP1-86019, RRID:AB_11002272
- Product name
- Rabbit Polyclonal CPS1 Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified. Specificity of human, canine CPS1 antibody verified on a Protein Array containing target protein plus 383 other non-specific proteins.
- Reactivity
- Human, Canine
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 0.1 ml
- Storage
- Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Submitted references Aberrant expression and distribution of enzymes of the urea cycle and other ammonia metabolizing pathways in dogs with congenital portosystemic shunts.
van Straten G, van Steenbeek FG, Grinwis GC, Favier RP, Kummeling A, van Gils IH, Fieten H, Groot Koerkamp MJ, Holstege FC, Rothuizen J, Spee B
PloS one 2014;9(6):e100077
PloS one 2014;9(6):e100077
No comments: Submit comment
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Western Blot: CPS1 Antibody [NBP1-86019] - Analysis in human liver tissue.
Supportive validation
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: CPS1 Antibody [NBP1-86019] - Staining of human liver shows high expression.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: CPS1 Antibody [NBP1-86019] - Staining of human kidney shows low expression as expected.
- Submitted by
- Novus Biologicals (provider)
- Main image
- Experimental details
- Immunohistochemistry-Paraffin: CPS1 Antibody [NBP1-86019] - Staining in human liver and kidney tissues using anti-CPS1 antibody. Corresponding CPS1 RNA-seq data are presented for the same tissues.